Xeris Pharmaceuticals (XERS)
(Delayed Data from NSDQ)
$7.72 USD
-0.58 (-6.99%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $7.70 -0.02 (-0.26%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
XERS 7.72 -0.58(-6.99%)
Will XERS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for XERS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XERS
What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?
Xeris Biopharma (XERS) Upgraded to Buy: Here's Why
XERS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
Other News for XERS
Is XERS showing upside potential? Crossed Above 20 Day Moving Average shows up after surging 8.21%
Stochastic Buy Signal appears for XERS after 2.68% move
Xeris Pharmaceuticals (XERS) Receives a Buy from H.C. Wainwright
Bollinger Band Squeeze appears for XERS after 1.49% move
XERS forms Stochastic Reached Oversold on September 15